Kissd: Ketamine Intramuscular Stepped System for Depression: The Holy Grail of Depression Is Our 100 Days of Freedom from Depression - Hiemstra, Robert C.
25,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
13 °P sammeln
  • Gebundenes Buch

"KISSD: Ketamine Intramuscular Stepped System for Depression" began as a guide to the administration of sub-anesthetic ketamine therapy for the treatment of depression, anxiety and PTSD. Its guiding light has been the KISSD process of ketamine administration. KISSD - Ketamine Intramuscular Stepped System for Depression - is a process for ketamine delivery that allows for a safe, comfortable but adequate dosage of ketamine to achieve the 100 days of freedom from depression that is possible. These results are unique in the history of the treatment of depression and show ketamine to heal…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
"KISSD: Ketamine Intramuscular Stepped System for Depression" began as a guide to the administration of sub-anesthetic ketamine therapy for the treatment of depression, anxiety and PTSD. Its guiding light has been the KISSD process of ketamine administration. KISSD - Ketamine Intramuscular Stepped System for Depression - is a process for ketamine delivery that allows for a safe, comfortable but adequate dosage of ketamine to achieve the 100 days of freedom from depression that is possible. These results are unique in the history of the treatment of depression and show ketamine to heal depression far more effectively and with far more safety than any medicine offered by modern psychiatry. This book provides the step-by-step checklist needed for any properly equipped clinic to administer this uniquely effective medicine. Whether a small clinic or academic mental health complex, ketamine is the depression drug of the future. Also discussed are larger issues surrounding the world of depression and its treatment, speculations on the nature of what is, exactly, depression, and the specifics of the darker sides of both Big Pharma and psychiatry.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Robert Hiemstra entered emergency physician while it was still in its pre-specialty status infancy, and served in many scattered emergency rooms in many varieties of culture for over forty years. This included both big city ERs and the most rural of traditional and Native American cultures. His career also included four years of emergency medicine in Dharan, Saudi Arabia. He completed his board certification in emergency medicine by way of the grandfathering option of the American College of Emergency Physicians. When the general anesthetic ketamine was recognized during the past two decades as an antidepressant of uniquely powerful and safe effectiveness, described by the science Nature as "the greatest contribution to psychiatry of the past half-century, Dr. Hiemstra saw a special opportunity and unmet need; after all, psychiatry is doing everything it can to suppress ketamine for its financial threat to its virtually worthless-for-depression SSRIs. Dr. Hiemstra realized that his emergency medicine experience could offer special insights into adapting this special medicine to the needs of the depressed, the anxious, and the sufferers of PTSD. And it did. Dr. Hiemstra has developed a system of ketamine administration that has profound and powerful antidepressant effects simply unequalled in pharmacologic medicine. Specifically, 75% of patients treated with Dr. Hiemstra's process are given 100 days of freedom from depression with no drug side effects because no drugs are being taken. The name of the process is KISSD, an acronym for Ketamine Intramuscular Stepped System for Depression, and the name we have chosen for those 100 days is the "Holy Grail of Depression." Emergency Medicine served Dr. Hiemstra well, but psychiatry was the field that all through medical school he assumed he would be entering. Dr. Hiemstra's becoming a psychiatrist did not come to fruition initially, but both Big Pharma and psychiatry are in the midst of great dysfunction on many fronts. Their DSM system of defining disease simply doesn't work, and the same can be said of their mainstay pharmacologic agents, the SSRIs and SNRIs. But both are making huge money selling worthless products to their patients suffering the worst disease known to Humankind, depression. Dr. Hiemstra's statistics for treating depression show the KISSD system to be at least 30-40 times as effective as antidepressants as are psychiatry's SSRIs. But Dr. Hiemstra is not here to be in simple capitalistic competition with psychiatry, as in, "My ketamine is better than their SSRIs: Buy ketamine." Dr. Hiemstra's prime goal is to get psychiatry to see the errors of their ways, to stop doing more harm than help to their patients, and to utilize ketamine to effect major changes in depression, anxiety, and PTSD that is altering the lives for the worse of 60-100 million Americans. Only ketamine is poised to make these changes, and KISSD simply does it best.